Preferred Label : Bemcentinib;
NCIt synonyms : AXL Inhibitor BGB324; 1H-1,2,4-Triazole-3,5-diamine, 1-(6,7-Dihydro-5H-benzo(6,7)cyclohepta(1,2-C)pyridazin-3-yl)-N3-((7S)-6,7,8,9-tetrahydro-7-(1-pyrrolidinyl)-5H-benzocyclohepten-2-yl)-; WHO 10631;
NCIt definition : An orally available and selective inhibitor of the AXL receptor tyrosine kinase (UFO),
with potential antineoplastic activity. Upon administration, bemcentinib targets and
binds to the intracellular catalytic kinase domain of AXL and prevents its activity.
This blocks AXL-mediated signal transduction pathways and inhibits the epithelial-mesenchymal
transition (EMT), which, in turn, inhibits tumor cell proliferation and migration.
In addition, bemcentinib enhances chemo-sensitivity. AXL, a member of the TAM (TYRO3,
AXL and MER) family of receptor tyrosine kinases overexpressed by many tumor cell
types, plays a key role in tumor cell proliferation, survival, invasion and metastasis;
its expression is associated with drug resistance and poor prognosis.;
UNII : 0ICW2LX8AS;
InChIKey : KXMZDGSRSGHMMK-VWLOTQADSA-N;
CAS number : 1037624-75-1;
Molecule name : BGB 324; BGB-324; R-428;
NCI Metathesaurus CUI : CL777354;
Origin ID : C121854;
UMLS CUI : C4763383;
Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- concept_is_in_subset
- has_target
